



Docket No.: PF-0599-2 DIV

**Response Under 37 C.F.R. 1.116 - Expedited Procedure**  
**Examining Group 1644**

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Mail Stop: Appeal Brief-Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 6, 2003  
By: [Signature] Printed: D. Ellis

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

In re Application of: Yue et al.

Title: CELL JUNCTION PDZ PROTEIN

Serial No.: 09/909,005

Filing Date: July 18, 2001

Examiner: Haddad, M.

Group Art Unit: 1644

Mail Stop: Appeal Brief-Patents  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED  
MAY 12 2003  
TECH CENTER 1600/2600

**BRIEF ON APPEAL**

Sir:

Further to the Notice of Appeal filed February 28, 2003, and received by the USPTO on March 6, 2003, herewith are three copies of Appellants' Brief on Appeal. Authorized fees include the \$ 320.00 fee for the filing of this Brief.

This is an appeal from the decision of the Examiner finally rejecting claims 10, 30, 31, 33, 35-42 and 46 of the above-identified application.

**(1) REAL PARTY IN INTEREST**

The above-identified application is assigned of record to Incyte Pharmaceuticals, Inc. (now Incyte Corporation) (Reel 9692, Frame 0156), which is the real party in interest herein.

5/12/2003 AMONDAF1 00000017 090108 09909005

1 FC:1402 320.00 CH

105495

1

09/909,005

(2) RELATED APPEALS AND INTERFERENCES

Appellants, their legal representative and the assignee are not aware of any related appeals or interferences which will directly affect or be directly affected by or have a bearing on the Board's decision in the instant appeal.

(3) STATUS OF THE CLAIMS

Claims rejected: Claims 10, 30, 31, 33, 35-42 and 46  
Claims allowed: None.  
Claims objected to: Claim 45  
Claims canceled: Claims 1-9 and 11-28  
Claims withdrawn: Claims 29, 32, 34, 43 and 44  
Claims on Appeal: Claims 10, 30, 31, 33, 35-42 and 46 (A copy of the claims on appeal, as amended, can be found in the attached Appendix).

(4) STATUS OF AMENDMENTS AFTER FINAL

There were no amendments submitted after Final Rejection.

(5) SUMMARY OF THE INVENTION

Embodiments of Appellants' invention are directed to antibodies which specifically bind to polypeptides related to a human cell junction PDZ protein (CJPDZ). As described in the Specification at page 12, lines 10-23:

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A, 1B, and 1C. CJPDZ is 233 amino acids in length and has five potential protein kinase C phosphorylation sites at S52, T89, S181, T189, and T205. CJPDZ has chemical and structural similarity with C. elegans LIN-7 (GI 1685067; SEQ ID NO:3). CJPDZ and LIN-7 share 53% identity overall and 69% identity within the region from L25 to R204 of CJPDZ and from L117 to R295 of LIN-7, as shown in Figure 2. Within this region, CJPDZ contains a putative PDZ domain from R107 to T189 which shares 82% sequence identity with the PDZ domain of LIN-7. The GD dipeptide and asparagine residue found in nearly all PDZ domains are conserved in CJPDZ at G152, D153, and N159. In addition, the putative PDZ domain of CJPDZ contains eleven glycine residues, consistent with the glycine-

rich nature of nearly all PDZ domains. A fragment of SEQ ID NO:2 from about nucleotide 432 to about nucleotide 461 is useful in hybridization or amplification technologies to identify SEQ ID NO:2 and to distinguish between SEQ ID NO:2 and a related sequence. Northern analysis shows the expression of this sequence in mononuclear cells derived from umbilical cord blood, in the testis, in fetal lung, and in breast tissue.

These antibodies have a variety of utilities, in particular in expression profiling, and for diagnosis of conditions or diseases characterized by expression of CJPDZ, for toxicology testing, and for drug discovery (see the Specification, for example, at page 29, lines 20-27; and page 33, line 36 to page 37, line 10).

#### (6) THE FINAL REJECTIONS

Claims 10, 30, 31, 33, 35-42 and 46 stand rejected under 35 U.S.C. §112, first paragraph, based on the allegation that the claims are not commensurate in scope with the enabling disclosure. The Examiner has stated that the specification "does not reasonably provide enablement for any antibody which binds to any polypeptide comprising any naturally occurring amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1 in claims 10 and 46." (12/02/02 Final Office Action, at page 2).

Claims 10, 30, 31, 33, 35-42 and 46 also stand rejected under 35 U.S.C. §112, first paragraph, based on the allegation that the claims contain "subject matter which was not described in the specification in such a way as to reasonably convey to one of skill in the art that the inventor(s), at the time the application was filed, had possession of the claimed invention." (12/02/02 Final Office Action, at page 4) This rejection alleges in particular that "there is no described or art-recognized correlation or relationship between the structure of the invention, the CJPDZ protein and it's (sic) function ...Therefore, one of skill in the art would not envisage, based on the instant disclosure, the claimed genus of variants, wherein the variant has at least 90% sequence identity of SEQ ID NO:1 ". *Id.*

(7) ISSUES

1. Whether claims 10, 30, 31, 33, 35-42 and 46 meet the enablement requirement of 35 U.S.C. § 112, first paragraph.
2. Whether claims 10, 30, 31, 33, 35-42 and 46 meet the written description requirement of 35 U.S.C. §112, first paragraph.

(8) GROUPING OF THE CLAIMS

**As to Issue 1**

All of the claims on appeal are grouped together.

**As to Issue 2**

All of the claims on appeal are grouped together.

(9) APPELLANTS' ARGUMENTSIssue 2 – Enablement rejection

**The enablement rejection of claims 10, 30, 31, 33, 35-42 and 46 is in error; the use of the "variants" recited by these claims would not require undue experimentation for a person having skill in the art to be able to make and use the claimed antibodies.**

The Examiner has asserted that claims 10, 30, 31, 33, 35-42 and 46 are not patentable under the first paragraph of 35 U.S.C. §112 because the Specification allegedly does not provide enablement commensurate in scope with the claims. The Office Action does not dispute that an enabling disclosure has been provided for antibodies which specifically bind to polypeptides comprising the amino acid sequence of SEQ ID NO:1. Rather, the Action alleges that an enabling disclosure has not been provided for antibodies which specifically bind to the recited "variants" of SEQ ID NO:1.

At the outset, the use of the antibodies which specifically bind the recited "variants" of SEQ ID NO:1 should not be at issue. That is, these antibodies have the same uses as an antibody which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1. For example, the skilled artisan could use the claimed antibodies to purify a protein having an amino acid sequence comprising a variant sequence of SEQ ID NO:1 (See the Specification, for example, at page 41, lines 24-34). In another use, antibodies to variants of the amino acid sequence of SEQ ID NO: 1 can be used for drug screening purposes (See the Specification, for example, at page 33 line 36 to page 34 line 14). Note lines 9-10 on page 34 which state that "antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with CJPDZ." Additionally, antibodies which specifically bind to variants of SEQ ID NO:1 can be used, for example, in 2D-PAGE analysis for expression profiling related to toxicology testing, drug discovery and disease diagnosis. Thus, Appellants submit that the skilled artisan would readily know how to use antibodies to a "variant" of the sequence of SEQ ID NO: 1 and that undue experimentation would not be required.

Moreover, there should be no issue with how to make the antibodies *per se*. Methods for making antibodies are well known in the art, and are also described in the Specification at, for

example, pages 22-24. The same methods for producing antibodies to polypeptides which comprise SEQ ID NO:1 could be used to make antibodies which specifically bind "variants" of SEQ ID NO:1.

Thus, the rejection appears to be based on the presumption that one could not make the claimed antibodies because one would allegedly not be able to make the recited "variants" of SEQ ID NO:1 *per se*, which in turn are used to produce antibodies which specifically bind those proteins. Such, however, is not the case.

Note that claim 10 recites not only that the variant polypeptides are at least 90% identical to SEQ ID NO:1, but also have "*a naturally-occurring amino acid sequence.*" Through the process of natural selection, nature will have determined the appropriate amino acid sequences. Given the information provided by SEQ ID NO:1 (the amino acid sequence of CJPDZ) and SEQ ID NO:2 (the polynucleotide sequence encoding CJPDZ), one of skill in the art would be able to routinely obtain "a naturally-occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1." For example, the identification of relevant polynucleotides could be performed by hybridization and/or PCR techniques that were well-known to those skilled in the art at the time the subject application was filed and/or described throughout the Specification of the instant application. For example:

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature. (Specification at page 10, lines 28-32)

For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion of

carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art. (Specification at page 13, lines 25 to page 14, line 8)

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding CJPDZ or closely related molecules may be used to identify nucleic acid sequences which encode CJPDZ. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding CJPDZ, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably have at least 50% sequence identity to any of the CJPDZ encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:2 or from genomic sequences including promoters, enhancers, and introns of the CJPDZ gene. (Specification at page 30, lines 6-16)

See also Example VI at page 38.

Thus, one skilled in the art need not make and test vast numbers of polypeptides that are based on the amino acid sequence of SEQ ID NO:1. Instead, one skilled in the art need only screen a cDNA library or use appropriate PCR conditions to identify relevant polynucleotides/polypeptides that already exist in nature. By adjusting the nature of the probe or nucleic acid (*i.e.*, non-conserved, conserved or highly conserved) and the conditions of hybridization (maximum, high, intermediate or low stringency), one can obtain variant polynucleotides of SEQ ID NO:2 which, in turn, will allow one to make the variant polypeptides of SEQ ID NO:1 recited by the present claims. Conventional methods for making antibodies, such as those described at pages 22-24 of the Specification, could be used to make antibodies which specifically bind to the recited polypeptide variants.

The Examiner cited Coleman *et al.*, Abaza *et al.*, Lederman *et al.*, and Li *et al.*, as demonstrating that even a single amino acid change can alter protein function. However, these references are not relevant to the case at hand. In these cases, the mutations were "artificially" created in the laboratory and, therefore, are **not** analogous to molecular evolution, which is profoundly influenced by natural selection. For example, the deactivating mutations as described by these references would almost certainly not be tolerated in nature. Furthermore, it is clear that over the course of evolution, amino acid residues that are critical for protein function are **conserved**. Thus, the amino acid differences are likely to represent substitutions that do **not** alter protein function. Therefore, the teachings of these references are not relevant to the case at hand, which relates to naturally occurring amino acid sequences.

The Examiner further cites Ngo *et al.* and alleges that due to the fact that the relationships between the sequence of a protein/peptide and its tertiary structure (i.e., its activity) are not well understood and are not predictable, it would require an undue experimentation for one skilled in the art to arrive at polypeptides comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1. However, the document cited by the Examiner relating to structure-antigenicity relationships in proteins is simply not germane to whether one can make and use the polypeptide variants recited by the present claims. That is, regardless of the precise functional characteristics of the SEQ ID NO:1 variants, one can still make those polypeptide variants using the disclosure provided by the present Specification. The polypeptides could then be used in, for example, diagnostic testing, drug discovery, expression profiling, etc.

Furthermore, the Examiner's attention is also directed to the enclosed reference by Brenner *et al.* ("Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships," *Proc. Natl. Acad. Sci. USA* (1998) 95:6073-6078). Through exhaustive analysis of a data set of proteins with known structural and functional relationships and with <90% overall sequence identity, Brenner *et al.* have determined that 30% identity is a reliable threshold for establishing evolutionary homology between two sequences aligned over at least 150 residues. (Brenner *et al.*, pages 6073 and 6076.) Furthermore, local identity is particularly important in this case for assessing the significance of the alignments, as Brenner *et al.* further report that  $\geq 40\%$  identity over at least 70 residues is reliable in signifying homology



between proteins. (Brenner et al., page 6076.)

Claim 10 recites, *inter alia*, antibodies which specifically bind to "a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1." In accordance with Brenner et al, naturally occurring molecules may exist which could be characterized as CJPDZ-like proteins and which have as little as 30% identity over at least 150 residues to SEQ ID NO:1. The "90% variants" recited by the present claims have a variation that is far less than that of all potential CJPDZ-like proteins related to SEQ ID NO:1, i.e., those CJPDZ-like proteins having as little as 30% identity over at least 150 residues to SEQ ID NO:1. Therefore, one would expect the SEQ ID NO:1 variants recited by the present claims to have the functional activities of a CJPDZ-like protein.

As set forth in *In re Marzocchi*, 169 USPQ 367, 369 (CCPA 1971):

The first paragraph of § 112 ***requires nothing more than objective enablement.*** [emphasis added] How such a teaching is set forth, either by the use of illustrative examples or by broad terminology, is of no importance.

As a matter of Patent Office practice, then, a specification disclosure which contains a teaching of the manner and process of making and using the invention in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented *must* be take as in compliance with the enabling requirement of the first paragraph of § 112 *unless* there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

Contrary to the standard set forth in *Marzocchi*, the Examiner has failed to provide any ***reasons*** why one would doubt that the guidance provided by the present Specification would enable one to make and use the recited antibodies which specifically bind to the recited "variants" and fragments of SEQ ID NO:1. Hence, a *prima facie* case for non-enablement has not been established with respect to the claimed antibodies which specifically bind to the recited "variants" and fragments of SEQ ID NO:1.

For at least the above reasons, reversal of this rejection is requested.

## **Issue 2 – Written description rejection**

**The rejection of claims 10, 30, 31, 33, 35-42 and 46 is in error; the Specification**

**provides an adequate written description of the claimed invention including antibodies which specifically bind "90% variants" of SEQ ID NO:1.**

Claims 10, 30, 31, 33, 35-42 and 46 have been rejected under 35 U.S.C. §112, first paragraph, as allegedly containing subject matter which was not described in the Specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor, at the time the application was filed, had possession of the claimed invention. In particular, the rejection alleges that "there is no described or art-recognized correlation or relationship between the structure of the invention, the CJPZ protein and it's (sic) function ...Therefore, one of skill in the art would not envisage, based on the instant disclosure, the claimed genus of variants, wherein the variant has at least 90% sequence identity of SEQ ID NO:1 ." (12/02/02 Final Office Action, at page 4) This rejection is improper, as the claims define subject matter which is described in the Specification in such a way as to reasonably convey to one skilled in the art that the inventors had possession of the claimed subject matter at the time the application was filed.

The requirements necessary to fulfill the written description requirement of 35 U.S.C. § 112, first paragraph, are well established by case law.

... the applicant must also convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the "written description" inquiry, *whatever is now claimed*. *Vas-Cath, Inc. v. Mahurkar*, 19 U.S.P.Q.2d 1111, 1117 (Fed. Cir. 1991)

The Board's Attention is also drawn to the Patent and Trademark Office's own "Guidelines for Examination of Patent Applications Under the 35 U.S.C. § 112, para. 1", published January 5, 2001, which provide that:

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics<sup>42</sup> which provide evidence that applicant was in possession of the claimed invention,<sup>43</sup> i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics.<sup>44</sup> What is conventional or well known to one of ordinary skill in the art need not be disclosed in detail.<sup>45</sup> If a skilled artisan would have understood the inventor to be in possession of the claimed invention at the time of filing, even if every nuance of the claims is not explicitly described in the specification, then the adequate

description requirement is met.<sup>46</sup>

Thus, the written description standard is fulfilled by both what is specifically disclosed and what is conventional or well known to one skilled in the art.

**A. The Specification provides an adequate written description of the claimed antibodies which specifically bind to the recited "variants" of SEQ ID NO:1.**

The subject matter encompassed by claims 10, 30, 31, 33, 35-42 and 46 is either disclosed by the Specification or is conventional or well known to one skilled in the art.

First note that the "variant" language of independent claim 10 recites a "naturally-occurring polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1." The amino acid sequence of SEQ ID NO:1 is explicitly disclosed in the specification. (See, for example, the Sequence Listing and Figures 1A, 1B, 1C, and 2 of the Specification). Variants of SEQ ID NO:1 are described in the Specification at, for example, page 3, lines 10-16; page 11, lines 16-23; page 12, lines 24-27; and page 16, lines 15-17.

One of ordinary skill in the art would recognize polypeptide sequences which are variants having a polypeptide sequence at least 90% identical to SEQ ID NO:1. Given any naturally occurring polypeptide sequence, it would be routine for one of skill in the art to recognize whether it was a variant of SEQ ID NO:1. Accordingly, the specification provides an adequate written description of the recited polypeptide variants of SEQ ID NO:1. Moreover, the Specification describes antibodies which specifically bind the SEQ ID NO:1 polypeptides. ( See the Specification, for example, at page 4, lines 8-10; and pages 23-24.

**1. The present claims specifically define the claimed genus through the recitation of chemical structure**

Court cases in which "DNA claims" have been at issue (which are hence relevant to claims to proteins encoded by the DNA and antibodies which specifically bind the proteins) commonly emphasize that the recitation of structural features or chemical or physical properties are important factors to consider in a written description analysis of such claims. For example, in

*Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993), the court stated that:

If a conception of a DNA requires a precise definition, such as by structure, formula, chemical name or physical properties, as we have held, then a description also requires that degree of specificity.

In a number of instances in which claims to DNA have been found invalid, the courts have noted that the claims attempted to define the claimed DNA in terms of functional characteristics without any reference to structural features. As set forth by the court in *University of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997):

In claims to genetic material, however, a generic statement such as "vertebrate insulin cDNA" or "mammalian insulin cDNA," without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function.

Thus, the mere recitation of functional characteristics of a DNA, without the definition of structural features, has been a common basis by which courts have found invalid claims to DNA. For example, in *Lilly*, 43 USPQ2d at 1407, the court found invalid for violation of the written description requirement the following claim of U.S. Patent No. 4,652,525:

1. A recombinant plasmid replicable in procaryotic host containing within its nucleotide sequence a subsequence having the structure of the reverse transcript of an mRNA of a vertebrate, which mRNA encodes insulin.

In *Fiers*, 25 USPQ2d at 1603, the parties were in an interference involving the following count:

A DNA which consists essentially of a DNA which codes for a human fibroblast interferon-beta polypeptide.

Party Revel in the *Fiers* case argued that its foreign priority application contained an adequate written description of the DNA of the count because that application mentioned a potential method for isolating the DNA. The Revel priority application, however, did not have a description of any particular DNA structure corresponding to the DNA of the count. The court therefore found that the Revel priority application lacked an adequate written description of the subject matter of the count.

Thus, in *Lilly* and *Fiers*, nucleic acids were defined on the basis of functional characteristics and were found not to comply with the written description requirement of 35

U.S.C. § 112; *i.e.*, "an mRNA of a vertebrate, which mRNA encodes insulin" in *Lilly*, and "DNA which codes for a human fibroblast interferon-beta polypeptide" in *Fiers*. In contrast to the situation in *Lilly* and *Fiers*, the claims at issue in the present application define the polypeptides bound by the claimed antibodies in terms of chemical structure, rather than functional characteristics. For example, the language of independent claim 10 recites chemical structure to define the claimed genus:

10. An isolated antibody which specifically binds to an isolated polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1.

From the above it should be apparent that the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:1. In the present case, there is no reliance merely on a description of functional characteristics of the polypeptides specifically bound by the claimed antibodies. The polypeptides defined by the claims of the present application recite structural features, and cases such as *Lilly* and *Fiers* stress that the recitation of structure is an important factor to consider in a written description analysis of claims of this type. By failing to base his written description inquiry "on whatever is now claimed," the Examiner failed to provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in *Lilly* and *Fiers*.

## **2. The present claims do not define a genus which is "highly variant"**

Furthermore, the claims at issue do not describe a genus which could be characterized as "highly variant". Available evidence illustrates that, rather than being a large variable genus, the genus of polypeptides recited by the claims is of narrow scope.

In support of this assertion, the Board's attention is directed to the enclosed reference by Brenner et al. ("Assessing sequence comparison methods with reliable structurally identified

distant evolutionary relationships," Proc. Natl. Acad. Sci. USA (1998) 95:6073-6078). Through exhaustive analysis of a data set of proteins with known structural and functional relationships and with <90% overall sequence identity, Brenner et al. have determined that 30% identity is a reliable threshold for establishing evolutionary homology between two sequences aligned over at least 150 residues (Brenner et al., pages 6073 and 6076). Furthermore, local identity is particularly important in this case for assessing the significance of the alignments, as Brenner et al. further report that  $\geq 40\%$  identity over at least 70 residues is reliable in signifying homology between proteins (Brenner et al., page 6076).

Embodiments of the present invention are directed, *inter alia*, to antibodies which specifically bind cell junction PDZ related proteins, including cell junction PDZ proteins related to the amino acid sequence of SEQ ID NO:1. In accordance with Brenner et al., naturally occurring molecules may exist which could be characterized as cell junction PDZ proteins and which have as little as 30% identity over at least 150 residues to SEQ ID NO:1. The "variant language" of the present claims recites antibodies which specifically bind a polypeptide comprising "a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1" (note that SEQ ID NO:1 has 233 amino acid residues). This variation is far less than that of all potential cell junction PDZ proteins related to SEQ ID NO:1, i.e., those cell junction PDZ proteins having as little as 30% identity over at least 150 residues to SEQ ID NO:1.

### **3. The state of the art at the time of the present invention is further advanced than at the time of the *Lilly* and *Fiers* applications**

In the *Lilly* case, claims of U.S. Patent No. 4,652,525 were found invalid for failing to comply with the written description requirement of 35 U.S.C. § 112. The '525 patent claimed the benefit of priority of two applications, Application Serial No. 801,343 filed May 27, 1977, and Application Serial No. 805,023 filed June 9, 1977. In the *Fiers* case, party Revel claimed the benefit of priority of an Israeli application filed on November 21, 1979. Thus, the written description inquiry in those cases was based on the state of the art at essentially the "dark ages" of recombinant DNA technology.

The present application has a priority date of September 11, 1998. Much has happened in

the development of recombinant DNA technology in the 20 or so years from the time of filing of the applications involved in *Lilly* and *Fiers* and the present application. For example, the technique of polymerase chain reaction (PCR) was invented. Highly efficient cloning and DNA sequencing technology has been developed. Large databases of protein and nucleotide sequences have been compiled. Much of the raw material of the human and other genomes has been sequenced. With these remarkable advances, one of skill in the art would recognize that, given the sequence information of SEQ ID NO:1, and the additional extensive detail provided by the subject application, the present inventors were in possession of the claimed antibodies that bind specifically to "variants" of SEQ ID NO:1 at the time of filing of this application.

#### 4. Summary

The Examiner failed to base his written description inquiry "on whatever is now claimed." Consequently, the Examiner did not provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in cases such as *Lilly* and *Fiers*. In particular, the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:1. The courts have stressed that structural features are important factors to consider in a written description analysis of claims reciting nucleic acids and proteins. In addition, the genus of polypeptides recited by the present claims is adequately described, as evidenced by Brenner et al. Furthermore, there have been remarkable advances in the state of the art since the *Lilly* and *Fiers* cases, and these advances were given no consideration whatsoever in the position set forth by the Office Action.

For at least the reasons set forth above, the Specification provides an adequate written description of the polypeptide "variants" recited by the claims, and antibodies which specifically bind those polypeptides. Accordingly, Appellants respectfully submit that the rejection should be reversed.

(10) CONCLUSION

Appellants respectfully submit that the enablement and written description rejections are in contradiction to the law and are without merit. The rejections are, therefore, improper and should be reversed.


If the USPTO determines that any additional fees are due, the Commissioner is hereby authorized to charge Deposit Account No. 09-0108.

This brief is enclosed in triplicate

Respectfully submitted,

INCYTE CORPORATION

Date: 06 May 2003




Richard C. Ekstrom

Reg. No. 37,027

Direct Dial Telephone: (650) 843-7352

Date: 05/06/03



Joel Harris

Reg. No. 44,743

Direct Dial Telephone: (650) 845-4866

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 849-8886



**APPENDIX - CLAIMS ON APPEAL**

10. An isolated antibody which specifically binds to a polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1, and
- b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1.

30. The antibody of claim 10, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')<sub>2</sub> fragment, or
- e) a humanized antibody.

31. A composition comprising an antibody of claim 10 and an acceptable excipient.

33. A composition of claim 31, wherein the antibody is labeled.

35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibodies from said animal; and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

36. An antibody produced by a method of claim 35.

37. A composition comprising the antibody of claim 36 and a suitable carrier.

38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
- b) isolating antibody producing cells from the animal;
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
- d) culturing the hybridoma cells; and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

39. A monoclonal antibody produced by a method of claim 38.

40. A composition comprising the antibody of claim 39 and a suitable carrier.

41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

46. An isolated antibody of claim 10 which specifically binds to a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1.